Advanced Proteome Therapeutics Corporation is pleased to announce that it has entered into an agreement for a feasibility study with a leading global pharmaceutical company interested in evaluating APT's proprietary crosslinking technologies.
Per the agreement, APC will chemically modify a specified entity by site-specifically attaching it to a variety of carriers that are designed to afford improved properties in clinical settings. Key properties of the modified entities will then be evaluated. APC has developed technology and filed patent applications to cover its inventions in the area of protein modification which it believes provide important scientific and commercial advantages that could be demonstrated under the terms of the agreement.
"This agreement is an important step for Advanced Proteome Therapeutics as our scientists have developed several potential drugs and diagnostics that have advanced to testing stages, which have been an outgrowth of our platform technologies. The opportunity to apply our platform to a specific initiative of a leading global pharmaceutical company will accelerate its further development and expand its scope. This agreement positions our Company for ongoing collaborations, business agreements, and should stimulate interest from additional top-tier partners," said Alexander Krantz, President and CEO of APC.
"Having rebranded our protein modification technology to Swift Linkage Multivalent Technology(TM) (SLMT) has helped raise our visibility with pharmaceutical and biotechnology companies in search of novel broad-based platform technologies involving protein modification, and we anticipate moving forward on various applications of our SLMT(TM) platform."
No comments:
Post a Comment